HGF plasmid

GENETIC3 trials

Sponsors

AnGes USA, Inc.

Conditions

Arterial Occlusive DiseaseCritical Limb IschemiaIschemiaPeripheral Arterial DiseasePeripheral Vascular DiseaseUlcersVascular Diseases

Phase 2

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

CompletedNCT00060892

AnGes USA, Inc.Arterial Occlusive Disease, Ischemia, Peripheral Vascular Disease

Start: 2003-04-30End: 2007-01-31Updated: 2008-01-11

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

CompletedNCT00189540

AnGes USA, Inc.Arterial Occlusive Disease, Ischemia, Peripheral Vascular Disease +1

Start: 2005-08-31End: 2008-08-31Updated: 2021-10-28

A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

CompletedNCT02016755

AnGes USA, Inc.Critical Limb Ischemia, Peripheral Arterial Disease, Vascular Diseases

Start: 2013-11-30End: 2018-03-31Updated: 2021-01-22